HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (Nasdaq: FRGT, “Fr8Tech” or the “Company”), a technology-centric logistics company offering a diversified portfolio of AI software solutions designed to address key inefficiencies in the supply chain, today announced strong productivity gains across key operating metrics for customers and its internal operations. The Company's intelligence-led and automation-driven solutions are improving the pace, accuracy, and scale of customers’ freigh ...

Core Insights - Edesa Biotech, Inc. announced positive results from a Phase 3 study of paridiprubart, demonstrating a significant reduction in 28-day mortality across a broad patient population [1][2][3] Study Results - The study involved 278 patients, including 104 requiring invasive mechanical ventilation (IMV) and 174 non-IMV patients, showing a 27% relative reduction in mortality from 33% to 24% (p<0.001) [2][3] - In a subgroup of 174 non-IMV patients, paridiprubart reduced mortality from 23% to 15%, a 35% relative reduction (p<0.05) [4] - Exploratory analyses indicated consistent mortality reductions in patients with serious comorbidities, with overall adverse events being low and similar between treatment groups [5] Patent and Regulatory Developments - Edesa has filed provisional patent applications for paridiprubart's use in treating sepsis, acute kidney injury, and pneumonia, with core patents extending into the 2030s [6] - The company is advancing regulatory discussions and exploring strategic collaborations to accelerate development and broaden access [8] Future Studies and Presentations - Paridiprubart is being evaluated in a separate U.S. government-funded study with enrollment ongoing for approximately 200 subjects [9] - Edesa has been selected for an oral presentation at the ATS 2026 conference to share additional findings from the Phase 3 study [12] Mechanism and Background - Paridiprubart is a first-in-class anti-TLR4 antibody designed to modulate the immune response in various critical conditions, including ARDS, which has high mortality rates and limited treatment options [19][20] - ARDS accounts for 10% of ICU admissions globally, representing over 3 million patients annually [20] Company Overview - Edesa Biotech focuses on developing innovative treatments for inflammatory and immune-related diseases, with a clinical pipeline that includes both medical dermatology and respiratory therapeutic areas [21]

Core Insights - SemiCab has been awarded a pilot program with Hindustan Coca-Cola Beverages Private Limited to launch a transportation program on its collaborative freight platform, aiming to cut transportation costs and reduce empty miles for Coca-Cola India [1][2] Company Overview - Algorhythm Holdings, Inc. is a leading AI technology company focused on the growth of SemiCab, which addresses supply-chain problems globally through its AI-enabled, cloud-based Collaborative Transportation Platform [6] - SemiCab's platform utilizes artificial intelligence and machine learning to optimize freight logistics, enabling fully loaded round trips and dynamic route optimization, which leads to improved asset utilization and reduced empty backhaul miles [4][6] Industry Impact - The partnership with Coca-Cola India marks a significant milestone in SemiCab's expansion within India's fast-moving consumer goods (FMCG) sector, following recent contract wins with other industry leaders such as Procter & Gamble India and Unilever India [2][5] - The pilot program is designed to evaluate SemiCab's effectiveness in reducing empty miles and improving delivery efficiency, which could lead to a broader rollout of its solutions if successful [3][5]

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across i ...

Netanya, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, today announced the receipt of two new purchase orders from first-response units in two European countries. The first order is a repeat purchase from a police department in Europe. This customer has previously acquired and is actively using the Company’s advanced tactical headset systems and related communic ...

14:15 London, 16:15 Helsinki, 24 February 2026 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, NASDAQ: AFAGR) PROFIT WARNING – DECREASE IN EBITDA Stock Exchange Release The Board of Directors of Afarak Group SE (“Company”) estimates that despite higher revenue of 141.3 million Euro, EBITDA for the full year 2025 is at approximately 0.7 million Euro, compared to 2.6 million Euro in 2024.In the Interim financial release H1 2025 published on 15th August 2025, the Company stated the following expectat ...

Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp WEST ...

Keith Hopkins VP, Content Distribution & Marketing for TV One Networks SILVER SPRING, MD., Feb. 24, 2026 (GLOBE NEWSWIRE) -- TV One Networks today announced the appointment of Keith Hopkins as the new Vice President of Content Distribution & Marketing. Hopkins brings two decades of experience spanning content distribution, sports partnerships, and streaming strategy, having held senior leadership roles at Roku, Nexstar Media Group, Pac-12 Conference and NBCUniversal/Comcast. In his new role, Hopkins wil ...

Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp WEST ...

Collaboration powers secure international data sharing through the HiFi Solves Global ConsortiumMENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced a collaboration with DNAstack to power the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the collaboration enables secure international research — allowing genomic insights to travel ac ...